Abstract
It is likely that the Endothelial Dysfunction (ED) found in Hypertensive Disorders of Pregnancy (HDP) are evoked by the actions of multiple factors and several pathways. Then the discovery and the understanding of these converging pathways that contribute to ED and poor outcome of pregnancy can addressing potential molecules with are modulated by different drugs. The use of omics tools, such as transcriptome and proteome, may help in this field. Importantly, although the knowledge of ED in HDP and the mechanisms underlying these processes are now becoming increasingly understood, this is not corresponding to developments in drug development/uses. There are no investments of pharmacy industries in this field due probably to high-risk investment in pregnant treatment. Moreover, even with improvement in researches on the pathophysiology of gestational hypertensive diseases, drug therapy remains limited and, therefore, is a contributing factor to the maintenance of high rates of maternal mortality. Therefore, the current proposal will explore ED in HDP. We have divided it into five subprojects:SP1 - Endothelial dysfunction in pre-eclampsia: potential drugs and new pharmacological targets obtained from "omics" toolsSP2 - Blood pressure control in chronic hypertensive pregnant women with beetroot juice supplementation starting in the 2nd trimester (BEET_CH)SP3 - Evaluation of endothelial dysfunction in experimental model of preeclampsia-like symptoms induced by reduction of uterine perfusion pressure (RUPP) in pregnant ratsSP 4- Study of endocrine disruptors and sex hormones in PE (EDRs)SP 5 - Biomarkers and pharmacogenetics of antihypertensive therapy in preeclampsia. (AU)
| Articles published in Agência FAPESP Newsletter about the research grant: |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |